Coherus Oncology (CHRS) Profit After Tax (2013 - 2026)

Coherus Oncology has disclosed Profit After Tax across 14 years of filings, most recently posting -$36.9 million for Q1 2026.

• Profit After Tax for Q1 2026 came in at -$36.9 million, up 22.07% year-over-year; the trailing twelve-month figure through Mar 2026 was $170.0 million (up 239.59% YoY), and the FY2025 annual result was -$183.1 million, down 742.38% from the prior year.
• Profit After Tax came in at -$36.9 million for Q1 2026 at Coherus Oncology, up from -$46.3 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $297.8 million in Q2 2025 to a low of -$96.1 million in Q1 2022.
• The 5-year median for Profit After Tax is -$46.3 million (2025), against an average of -$22.3 million.
• Peak annual rise in Profit After Tax reached 2404.52% in 2025, while the deepest fall reached 314.07% in 2025.
• Coherus Oncology's Profit After Tax stood at -$58.9 million in 2022, then plunged by 35.3% to -$79.7 million in 2023, then surged by 36.35% to -$50.7 million in 2024, then rose by 8.58% to -$46.3 million in 2025, then rose by 20.31% to -$36.9 million in 2026.
• The last three Profit After Tax figures came in at -$36.9 million (Q1 2026), -$46.3 million (Q4 2025), and -$44.5 million (Q3 2025), per Business Quant data.